WO1995006718A3 - Procede de suppression de la reponse auto-immune - Google Patents

Procede de suppression de la reponse auto-immune Download PDF

Info

Publication number
WO1995006718A3
WO1995006718A3 PCT/US1994/009860 US9409860W WO9506718A3 WO 1995006718 A3 WO1995006718 A3 WO 1995006718A3 US 9409860 W US9409860 W US 9409860W WO 9506718 A3 WO9506718 A3 WO 9506718A3
Authority
WO
WIPO (PCT)
Prior art keywords
autoimmune response
methods
transcribes
suppressing
suppressing autoimmune
Prior art date
Application number
PCT/US1994/009860
Other languages
English (en)
Other versions
WO1995006718A2 (fr
Inventor
Douglas J Jolly
Michael J Irwin
John F Warner
Thomas W Dubensky Jr
Carlos E Ibanez
Original Assignee
Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viagene Inc filed Critical Viagene Inc
Priority to AU78699/94A priority Critical patent/AU7869994A/en
Priority to JP7508256A priority patent/JPH09503655A/ja
Priority to EP94929752A priority patent/EP0716692A1/fr
Publication of WO1995006718A2 publication Critical patent/WO1995006718A2/fr
Publication of WO1995006718A3 publication Critical patent/WO1995006718A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cellules tissulaires d'un animal transformées à l'aide d'un vecteur de recombinaison qui (a) exprime une protéine ou une partie active de ladite protéine, (b) transcrit un message non codant ou (c) transcrit un ribozyme capable d'inhiber la présentation d'antigènes du complexe majeur d'histocompatiblité (MHC), destinées à être utilisées pour supprimer une réponse auto-immune. Dans un aspect associé, lesdites cellules sont transformées avec au moins deux protéines, deux messages non codants ou deux ribozymes ou des combinaisons de ceux-ci.
PCT/US1994/009860 1993-09-03 1994-09-02 Procede de suppression de la reponse auto-immune WO1995006718A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU78699/94A AU7869994A (en) 1993-09-03 1994-09-02 Methods of suppressing autoimmune response
JP7508256A JPH09503655A (ja) 1993-09-03 1994-09-02 自己免疫応答の抑制方法
EP94929752A EP0716692A1 (fr) 1993-09-03 1994-09-02 Procede de suppression de la reponse auto-immune

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11698393A 1993-09-03 1993-09-03
US08/116,983 1993-09-03

Publications (2)

Publication Number Publication Date
WO1995006718A2 WO1995006718A2 (fr) 1995-03-09
WO1995006718A3 true WO1995006718A3 (fr) 1995-04-06

Family

ID=22370406

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/009860 WO1995006718A2 (fr) 1993-09-03 1994-09-02 Procede de suppression de la reponse auto-immune

Country Status (5)

Country Link
EP (1) EP0716692A1 (fr)
JP (1) JPH09503655A (fr)
AU (1) AU7869994A (fr)
CA (1) CA2158932A1 (fr)
WO (1) WO1995006718A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US6692910B2 (en) 1997-07-28 2004-02-17 The University Of Connecticut Inhibition of a target messenger RNA with a modified U1 small nuclear RNA
EP1036165A4 (fr) * 1997-12-04 2003-05-14 Isis Pharmaceuticals Inc Rnase humaine, compositions et leurs utilisations
US20030134809A1 (en) * 2001-12-17 2003-07-17 Isis Pharmaceuticals Inc. Antisense modulation of ABC transporter MHC 1 expression
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
FR2852021B1 (fr) * 2003-03-04 2007-12-07 Methodes et outils pour le criblage d'arn actifs in cellulo
DE112004002914A5 (de) * 2004-05-06 2007-05-24 Medizinische Hochschule Hannover Verbindungen und Verfahren zur Immunsuppression
US8236771B2 (en) * 2004-05-18 2012-08-07 National Institute Of Transplantation Foundation Vectors and methods for long-term immune evasion to prolong transplant viability

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992007071A1 (fr) * 1990-10-19 1992-04-30 The Board Of Trustees Of The University Of Illinois Methodes et applications relatives a des elements suppresseurs genetiques efficaces
WO1993002690A1 (fr) * 1991-08-02 1993-02-18 The General Hospital Corporation Diagnostic et traitement de maladies auto-immunes
WO1993014769A1 (fr) * 1992-01-31 1993-08-05 The Regents Of The University Of California Procede de production de cellules donneuses universelles
EP0601585A2 (fr) * 1992-12-09 1994-06-15 Enzo Therapeutics, Inc. Acide nucléique pour l'inhibition ou la régulation des fonctions d'un gène de la réponse immunitaire, méthode employant le-dit acide nucléique et système immuno-compatible contenant le-dit acide nucléique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles
WO1992007071A1 (fr) * 1990-10-19 1992-04-30 The Board Of Trustees Of The University Of Illinois Methodes et applications relatives a des elements suppresseurs genetiques efficaces
WO1993002690A1 (fr) * 1991-08-02 1993-02-18 The General Hospital Corporation Diagnostic et traitement de maladies auto-immunes
WO1993014769A1 (fr) * 1992-01-31 1993-08-05 The Regents Of The University Of California Procede de production de cellules donneuses universelles
EP0601585A2 (fr) * 1992-12-09 1994-06-15 Enzo Therapeutics, Inc. Acide nucléique pour l'inhibition ou la régulation des fonctions d'un gène de la réponse immunitaire, méthode employant le-dit acide nucléique et système immuno-compatible contenant le-dit acide nucléique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
H. BROWNE ET AL.: "A complex between the MHC class I homologue encoded by human cytomegalovirus and beta2 microglobulin.", NATURE, vol. 347, no. 6295, 25 October 1990 (1990-10-25), LONDON, GB, pages 770 - 772 *
H-G. BURGERT ET AL.: ""E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 84, no. 5, March 1987 (1987-03-01), WASHINGTON DC, USA, pages 1356 - 1360 *

Also Published As

Publication number Publication date
EP0716692A1 (fr) 1996-06-19
JPH09503655A (ja) 1997-04-15
CA2158932A1 (fr) 1995-03-09
WO1995006718A2 (fr) 1995-03-09
AU7869994A (en) 1995-03-22

Similar Documents

Publication Publication Date Title
AU2001278797A1 (en) Expression vector using for animal cell
GR3023329T3 (en) Plasma and recombinant protein formulations in low ionic strength media
CA2120514A1 (fr) Sequence synthetique d'adn a activite insecticide amelioree dans le mais
AU7158398A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
WO2000054813A3 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil
EP2278021A3 (fr) Vecteurs d'expression, systèmes de transfection et procédé d'utilisation correspondant
WO2000025725A3 (fr) Antagonistes fonctionnels de l'activite hedgehog
WO1998013500A3 (fr) Virus mva de recombinaison exprimant des antigenes du virus de dengue et utilisation de ces derniers dans des vaccins
WO2001038548A3 (fr) Vecteurs capables d'immortaliser des cellules ne se divisant pas, et cellules immortalisees au moyen de ces vecteurs
WO1995006718A3 (fr) Procede de suppression de la reponse auto-immune
WO1997020933A3 (fr) VARIANTES MUTATIONNELLES DE PROTEINES DE GENES Ob CHEZ LES MAMMIFERES
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
CA2306449A1 (fr) Generation rapide de lignees cellulaires mammiferes stables produisant des niveaux eleves de proteines recombinantes
WO2001012660A3 (fr) Proteines humaines a domaines hydrophobes et adn codant pour ces proteines
EP0754229A1 (fr) L'alfamine, une proteine albuminoide serique humaine
WO1997028104A3 (fr) Systemes tampons pour la stabilisation de preparations pharmaceutiques
WO2001002563A3 (fr) Proteines humaines ayant des domaines hydrophobes et adn codant pour ces proteines
WO2001096392A3 (fr) Molecules 22109, constituant un nouveau membre de la famille des thioredoxines humaines et utilisations correspondantes
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
WO1995006717A3 (fr) Procedes de suppression des rejets de greffes
WO1995006744A3 (fr) Procedes de suppression de la reponse immunitaire par therapie genique
AU8769791A (en) Pharmaceutically active proteins comprising an active protein and an integrinaffinity sequence
FI924494A0 (fi) Oekad produktion av avsoendrarde proteiner i eukaryotiska rekombinantceller
IL146191A0 (en) Viral expression vectors
WO2001090321A3 (fr) 55158, une nouvelle anhydrase carbonique humaine et son utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2158932

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994929752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994929752

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994929752

Country of ref document: EP